MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12896-025-01000-5

Медицинская библиотека · BMC biotechnology · 2025

Biomimetic nanoparticles coated with ScFv-modified macrophage membranes for siRNA delivery to relieve brain metastases of lung cancer.

Lu Yuan, Qiao Yan, Wu Ting, Zhang Yijing, Shi JiaXin, Jiang Jun

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

In China, lung cancer stands as the leading cause of cancer-related deaths, often resulting in brain metastases (BM) that severely compromise patients' quality of life and reduce survival outcomes. The delivery of drugs to the brain is further complicated by the blood-brain barrier (BBB). To address this, we developed EGFR single-chain fragment variable (scFv)-modified macrophage membrane liposomes (scFv-MML) encapsulating LPCAT1 siRNA (scFv-MML@LPCAT1si) as a targeted therapy for non-small cell lung cancer (NSCLC) BM.

METHODS

EGFR scFv-pcDNA3.1(-) plasmids were transfected into RAW 264.7 cells to generate RAW 264.7-scFv cells. Macrophage membranes were isolated from these cells and used to coat liposomes (Lip) encapsulating LPCAT1 siRNA via extrusion. The cellular uptake, LPCAT1 silencing, and anti-tumor efficacy of scFv-MML@LPCAT1si were evaluated in vitro using PC9 lung cancer cells. In vivo studies were performed in a mouse model of NSCLC BM to assess tumor targeting, accumulation, and therapeutic effects.

RESULTS

In vitro, scFv-MML@LPCAT1si exhibited superior cellular uptake and silencing of LPCAT1 expression in EGFR-positive PC9 cells compared to control liposomes, leading to increased cell apoptosis and decreased proliferation. In vivo, scFv-MML@LPCAT1si showed improved tumor targeting and accumulation in the brain, effectively slowing tumor growth and reducing body weight loss in mice with NSCLC BM. The biodistribution study revealed sustained tumor fluorescence intensity for more than 24 h after injection, with significant retention of siRNA within the tumor site. No significant systemic toxicity or organ damage was observed in mice treated with scFv-MML@LPCAT1si.

CONCLUSIONS

Our findings suggest that scFv-MML@LPCAT1si represents a promising targeted therapy for NSCLC BM, leveraging the unique properties of scFv-MML to traverse the BBB and deliver therapeutic payloads to tumor sites with high accuracy and efficiency.

Для цитирования: Lu Yuan, Qiao Yan, Wu Ting, Zhang Yijing, Shi JiaXin, Jiang Jun. Biomimetic nanoparticles coated with ScFv-modified macrophage membranes for siRNA delivery to relieve brain metastases of lung cancer.. BMC biotechnology. 2025. DOI: 10.1186/s12896-025-01000-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.